Medical Coverage Policy | Chelation Therapy for Off-Label Uses
Defines Blue Cross Blue Shield Rhode Island's coverage position for chelation therapy when used for off-label (non-FDA-approved) indications in Commercial Products, lists excluded/standard FDA-approved indications, coding guidance including a non-reimbursable infusion code and a Chemical Endarterectomy code with related diagnosis exclusions.
No material clinical or coverage changes.
Coverage Summary
Defines Blue Cross Blue Shield Rhode Island's coverage position for chelation therapy when used for off-label (non-FDA-approved) indications in Commercial Products. Off-label applications of chelation therapy for the following conditions are considered not medically necessary: Alzheimer disease; Atherosclerotic cardiovascular disease; Arthritis (including rheumatoid arthritis); Autism spectrum disorder; Diabetes; Multiple sclerosis.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.